July 23, 2022
1 min watch
Save
VIDEO: CST fluctuations not common with Port Delivery System with ranibizumab
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW YORK — In this Healio Video Perspective from the ASRS meeting, Veeral S. Sheth, MD, MBA, FASRS, FACS, discusses phase 3 results from the Archway trial.
The trial examined central subfield thickness fluctuations in patients with neovascular age-related macular degeneration treated with the Port Delivery System with ranibizumab, now known as Susvimo.
Published by:
Sources/Disclosures
Collapse
Source:
Sheth VS, et al. Central subfield thickness fluctuations and their impact on vision outcomes over 96 weeks in the Archway trial of the PDS. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Disclosures:
Sheth reports consulting for Genentech/Roche.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.